Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mycosis fungoides and Sézary syndrome: Australian clinical practice statement.
Bhabha FK, McCormack C, Wells J, Campbell BA, Newland K, Lade S, Buelens O, Joske D, Shortt J, Mapp S, Radeski D, Hertzberg M, Khot A, Van Der Weyden C, Khoo C, Hawkes E, Prince HM. Bhabha FK, et al. Among authors: joske d. Australas J Dermatol. 2021 Feb;62(1):e8-e18. doi: 10.1111/ajd.13467. Epub 2020 Dec 26. Australas J Dermatol. 2021. PMID: 33368169 Review.
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, Stetler-Stevenson M, Lade S, Fojo AT, Bates SE. Piekarz RL, et al. Among authors: joske d. J Clin Oncol. 2009 Nov 10;27(32):5410-7. doi: 10.1200/JCO.2008.21.6150. Epub 2009 Oct 13. J Clin Oncol. 2009. PMID: 19826128 Free PMC article. Clinical Trial.
Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data.
Bates SE, Eisch R, Ling A, Rosing D, Turner M, Pittaluga S, Prince HM, Kirschbaum MH, Allen SL, Zain J, Geskin LJ, Joske D, Popplewell L, Cowen EW, Jaffe ES, Nichols J, Kennedy S, Steinberg SM, Liewehr DJ, Showe LC, Steakley C, Wright J, Fojo T, Litman T, Piekarz RL. Bates SE, et al. Among authors: joske d. Br J Haematol. 2015 Jul;170(1):96-109. doi: 10.1111/bjh.13400. Epub 2015 Apr 19. Br J Haematol. 2015. PMID: 25891346 Free PMC article. Clinical Trial.
Frequency of bowel perforation and impact of bowel rest in aggressive non-Hodgkin lymphoma with gastrointestinal involvement.
Chin CK, Tsang E, Mediwake H, Khair W, Biccler J, Hapgood G, Mollee P, Nizich Z, Joske D, Radeski D, Cull G, Villa D, El-Galaly TC, Cheah CY. Chin CK, et al. Among authors: joske d. Br J Haematol. 2019 Mar;184(5):826-828. doi: 10.1111/bjh.15173. Epub 2018 Apr 20. Br J Haematol. 2019. PMID: 29676487 Free article. Clinical Trial. No abstract available.
Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation.
Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J, Joske D, Grigg A, McKendrick J, Prosser I, Lowenthal R, Deveridge S, Taylor K; Australasian Leukemia and Lymphoma Group. Spencer A, et al. Among authors: joske d. Bone Marrow Transplant. 2005 May;35(10):971-7. doi: 10.1038/sj.bmt.1704946. Bone Marrow Transplant. 2005. PMID: 15778725 Clinical Trial.
95 results